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Twist1 promotes epithelial-to-mesenchymal transi-
tion (EMT), invasion, metastasis, and cancer stem
cell (CSC) properties. However, it remains unclear
whether Twist1 is also required for tumor initiation
and whether Twist1-induced cancer stemness and
EMT are functionally linked. Using a conditional dele-
tion of Twist1 at different stages of skin carcinogen-
esis, we show that Twist1 is required for skin tumor
initiation and progression in a gene-dosage-de-
pendent manner. Moreover, conditional ablation of
Twist1 in benign tumors leads to increased apoptosis,
reduced cell proliferation, and defective tumor main-
tenance and propagation independently of its EMT-
inducing abilities. Concomitant deletion of Twist1
and p53 rescues the apoptotic response, but not the
cell proliferation and propagation defects. These re-
sults reveal that Twist1 is required for tumor initiation
and maintenance in a p53-dependent and -indepen-
dent manner. Importantly, our findings also indicate
that tumor stemness and EMT can be regulated by
distinct mechanisms.
INTRODUCTION
The epithelial-to-mesenchymal transition (EMT) is a cellular pro-
cess during which epithelial cells lose their adhesion properties
and acquire mesenchymal features allowing their migration
and invasion (Kalluri and Weinberg, 2009; Nieto, 2013; Thiery
et al., 2009). EMT is essential during embryonic development
for gastrulation, neurogenesis, and other developmental pro-
grams during morphogenesis (Nieto, 2013). The EMT program
is activated in a wide variety of cancer cells as they leave the pri-
mary tumor and colonize distant organs and form metastases
(Nieto, 2013; Puisieux et al., 2014). EMT has also been reported
to suppress tumor apoptosis and oncogene-induced senes-
cence (Ansieau et al., 2008; Burns et al., 2013; Emadi Baygi
et al., 2010; Kwok et al., 2007; Lee and Bar-Sagi, 2010; Maestroet al., 1999; Sayan et al., 2009; Tran et al., 2012; Valsesia-Witt-
mann et al., 2004) and to produce cancer cells with stem cell-
like properties (Mani et al., 2008; Masui et al., 2014; Morel
et al., 2008; Wellner et al., 2009; Zhou et al., 2014). Transcription
factors such as Twist, Snail, Zeb, and FoxC families are ex-
pressed in different cancers, and their overexpression induces
EMT as well as cancer stem cell (CSC)-properties in a variety
of cancer cell lines (Mani et al., 2008; Morel et al., 2008; Nieto,
2013; Puisieux et al., 2014).
Twist1, a basic-helix-loop-helix transcription factor, is one of
the EMT-inducer prototypes (Ansieau et al., 2010). Twist1 dele-
tion in mice leads to failure in neural tube closure associated
with defects in the formation of the head mesenchyme and
limb buds (Chen and Behringer, 1995). Twist1 is expressed in tu-
mors of different origins such as sarcomas, gliomas, squamous
cell carcinoma (SCCs), breast cancers, andmelanomas (Ansieau
et al., 2010). Mechanistically, Twist1 overexpression has been
shown to rescue Myc-induced apoptosis through inhibition of
p53 (Maestro et al., 1999; Valsesia-Wittmann et al., 2004). Twist1
knockdown decreases the metastatic potential of mammary tu-
mor cell lines (Yang et al., 2004). In addition, Twist1 overexpres-
sion induces EMT and E-cadherin repression, suggesting that
Twist1 promotes metastasis by inducing EMT (Morel et al.,
2012; Tsai et al., 2012; Yang et al., 2004). In addition to these
antiapoptotic and prometastatic roles, Twist1 overexpression
in mammary epithelial and cancer cell lines has been shown to
promote their ability to self-renew as mammospheres in vitro
and to engraft into immunodeficient mice, suggesting that Twist1
promotes tumor stemness (Mani et al., 2008; Morel et al., 2008).
However, to what extent these different functions of Twist1
including its effect on EMT, stemness, proliferation, and
apoptosis are functionally linked or whether these functions
are independently regulated by Twist1 remains unknown. Also,
while the role of Twist1 in cancer cell survival (Ansieau et al.,
2008; Burns et al., 2013; Hasselblatt et al., 2009; Kwok et al.,
2007; Lee and Bar-Sagi, 2010; Maestro et al., 1999; Tran et al.,
2012; Valsesia-Wittmann et al., 2004) and progression by
inducing invasion and extravasation through EMT is well-estab-
lished both in vitro and in vivo (Elias et al., 2005; Hasselblatt et al.,
2009; Lee et al., 2006; Mikheeva et al., 2010; Tsai et al., 2012;
Yang et al., 2004; Yuen et al., 2007), the role of Twist1 in the early
steps of tumor initiation remains elusive. Here, we used skinCell Stem Cell 16, 67–79, January 8, 2015 ª2015 Elsevier Inc. 67
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Figure 1. Twist1 Is Expressed at the Early
Stages of Skin Tumorigenesis
(A) qRT-PCR analysis of Twist1 mRNA expression
performed on FACS isolated normal interfolicular
epidermis (IFE) and tumor cells. Data were
normalized to normal IFE (n = 8/condition).
(B) Western blot for Twist1 was performed
on FACS isolated normal IFE cells, genetically
induced papilloma and SCC.
(C) Twist1 IHC performed on skin and tumor
sections.
(D) Quantification of the proportion of Twist1
positive tumors.
(E) Quantification of the proportion of Twist1 pos-
itive epithelial cells by IHC, showing the increase of
the proportion of Twist1 positive cells in invasive
SCCs (n = 8/condition); dermis (Der); epithelium
(epi); and stroma (str).
Scale bars, 50 mm (see also Figures S1 and S2).
Error bars represent SEM.
Cell Stem Cell
Twist1 in Skin Tumorigenesistumorigenesis as a model to investigate these important and
open questions. Mouse skin SCC is an ideal model to tackle
these questions, as skin tumors arise from mutations in the
Ras gene (Kemp, 2005), which have been previously shown to
synergize with Twist1 during tumorigenesis (Morel et al., 2012).
Skin tumorigenesis can be clearly separated into different stages
including tumor initiation, malignant progression, andmetastasis
(Kemp, 2005). Finally, skin SCCs contain cells with CSC proper-
ties characterized by enhanced propagating capacity following
their serial transplantation into immunodeficient mice (Boumahdi
et al., 2014; Lapouge et al., 2012; Malanchi et al., 2008; Schober
and Fuchs, 2011).
In this study, using conditional deletion of Twist1 at different
stages of skin tumorigenesis, we investigated the different func-
tions of Twist1 and their interdependence during tumor initiation,
maintenance, propagation, and malignant progression. We68 Cell Stem Cell 16, 67–79, January 8, 2015 ª2015 Elsevier Inc.found that Twist1 is expressed at the
earliest step of tumorigenesis and is
essential for the initiation and malignant
progression of skin tumors in a gene-
dosage-dependent manner. Conditional
deletion of Twist1 in pre-existing tumors
demonstrates the essential role of Twist1
in tumor maintenance. Twist1 inhibits
oncogene-induced apoptosis in a p53-
dependent manner, while the ability of
Twist1 to promote tumor cell proliferation
and propagation is regulated by a p53-in-
dependent mechanism. Strikingly, these
oncogenic functions of Twist1 are not
dependent upon its ability to induce EMT.
RESULTS
Twist1 Is Expressed at the Early
Stages of Skin Tumorigenesis
Twist1 has been detected in tumor prop-
agating cells (TPCs) of mouse skin SCCs
(Lapouge et al., 2012; Schober andFuchs, 2011), and Twist1 overexpression promotes malignant
progression of skin tumors (Morel et al., 2012; Tsai et al.,
2012). However, the temporal dynamic of Twist1 expression,
particularly during the early stages of skin tumorigenesis, re-
mains to be established. To address this question, we measured
Twist1 mRNA levels by quantitative (q)RT-PCR in normal skin
epidermis, in DMBA (9, 10-dimethyl-1, 2-benzanthracene)/TPA
(12-O-tetradecanoyl phorbol-13-acetate), and genetically
(K14CreER:KRasG12D and K14CreER:KRasG12D:p53fl/fl) induced
papilloma and SCCs isolated by fluorescence associated cell
sorting (FACS) (Figure 1A and Figure S1A available online).
Twist1 mRNA was upregulated by 100-fold in papilloma as
compared to normal epidermis, and its expression further
increased in SCCs (Figure 1A).
Twist1 protein was undetectable in normal epidermal cells by
western blot (Figure 1B) and immunohistochemistry (Figures 1
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Figure 2. Twist1 Is Critical for Skin Tumor
Initiation
(A) Genetic strategy used to study the role of
Twist1 during skin tumor initiation.
(B) PCR for Twist1 flox, deleted (Twist1DEx1) and
wild-type alleles.
(C) Picture of representative 10-week-old Twist1fl/fl
(Ctrl) and K14Cre:Twist1fl/fl mice, showing that
Twist1cKOepidermiswasmacroscopically normal.
(D) Immunostaining for b4 integrin and K10 in
control (Ctrl), showing that Twist1cKO epidermis is
microscopically normal.
(E) Strategy used to determine the impact of
Twist1 deletion in epidermal cells on skin carci-
nogenesis.
(F) Picture of representative Ctrl and K14Cre:
Twist1fl/fl mice 24 weeks following the first DMBA
application, showing the absence of skin tumors in
K14Cre:Twist1fl/fl mice.
(G) Percentage of Ctrl and K14Cre:Twist1fl/fl mice
with skin tumors over time. p < 0.0001 by log rank
test.
(H) Average number of skin tumors on Ctrl and
K14Cre:Twist1fl/fl mice 40 weeks following the first
DMBA application. p < 0.0001 by unpaired t test.
Cell Stem Cell
Twist1 in Skin Tumorigenesisand S1B–S1D); only fibroblasts from the dermis and the
mesenchymal part of the hair follicle, called the dermal papillae,
expressed Twist1 in the normal skin (Figure 1C). Twist1 was ex-
pressed in some epidermal cells following KRas-activation or
following DMBA/TPA treatment, prior the appearance of benign
tumors (Figure 1C), but not in hyperplasia induced by TPA or ret-
inoic acid treatment in the absence of oncogenic mutations (Fig-
ures S1C and S1D). Twist1 was expressed in the vast majority of
DMBA/TPA and genetically induced (KRasG12D/p53 conditional
knockout [cKO]) skin tumors (Figure 1D), and the level of Twist1
further increased in SCCs (Figures 1A–1C). In addition to the in-
crease of Twist1 expression, Twist1 was also expressed in more
cells in SCC (50%) as compared to papilloma (15%) (Figure 1E).
These results indicate that the induction of Twist1 expression is
an early event during mouse skin tumorigenesis and precedes
tumor development.
To investigate the relevance of our data to human SCCs, we
analyzed Twist1 expression in a series of 32 SCCs and five
normal skins. As found in the mouse skin, Twist1 was not ex-
pressed in the normal human epidermis and was expressed
only in dermal cells (Figure S2A). However, more than 50%of hu-
man skin SCCs (Figure S2B) were positive for Twist1, showing
that Twist1 is expressed in both mouse and human skin SCCs.
Twist1 Is Critical for Skin Tumor Initiation
While many studies have demonstrated a role for Twist1 in tumor
cell survival (Ansieauet al., 2008;Kwoket al., 2007;Maestro et al.,Cell Stem Cell 16, 67–1999; Tran et al., 2012; Valsesia-Wittmann
et al., 2004) and propagation (Mani et al.,
2008; Mikheeva et al., 2010; Morel et al.,
2008), the role of Twist1 during tumor
initiation has not been yet investigated.
To determine whether Twist1 regulates
the early steps of skin tumorigenesis, weconditionally deleted Twist1 in the developing skin epidermis us-
ing theK14-CREallele (K14Cre:Twist1fl/fl), which is active as early
as E12 and results in the deletion of the Twist1 floxed alleles in the
skin epidermis (Figures 2A and 2B). K14Cre:Twist1fl:fl mice were
born at the expected Mendelian ratio; these mice were indistin-
guishable morphologically and histologically from control mice
at 10 weeks of age (Figures 2C and 2D). These results indicate
that Twist1 expression in the skin epidermis is not required for
the morphogenesis, postnatal growth, and adult homeostasis
of the skin epidermis. To assess the role of Twist1 during skin
tumorigenesis, we treated K14Cre:Twist1fl:fl mice and their con-
trol littermateswithDMBA/TPA. In the 40weeks following the first
DMBA administration (Figure 2E), only a small fraction (14%) of
the K14Cre:Twist1fl/fl mice developed one or two tumors, while
all of the control mice developed on average eight tumors per
mouse (Figures 2F–2H). These results indicate that Twist1 con-
trols skin tumor initiation. The rare tumors observed on Twist1
cKO mice were macroscopically and microscopically similar to
the ones that developed on control animals and may arise from
distinct genetic and/or epigenetic mechanisms that may render
Twist1 dispensable to tumor initiation.
Twist1 Regulates Tumor Initiation and Progression
in a Dose-Dependent Manner
Since Twist1 expression increases with tumor progression, we
also assessed whether Twist1 is required for malignant progres-
sion by decreasing Twist1 gene dosage in a genetic/inducible79, January 8, 2015 ª2015 Elsevier Inc. 69
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Figure 3. Twist1 Regulates Tumor Initiation
and Progression in a Dose-Dependent
Manner
(A and B) Genetic strategy (A) and experimental
design (B) used to assess gene dosage require-
ment of Twist1 for tumor initiation and progression.
(C) Average number of papilloma and SCC on
K14CreER:KRasG12D:p53cKO, K14CreER:KRasG12D:
p53cKO:Twist1fl/fl, and K14CreER:KRasG12D:p53cKO:
Twist1fl/+. p < 0.0001 by Kruskal-Wallis test followed
by Dunn’s multiple comparisons test (n = 7/geno-
type).
(D–F) Hematoxylin/Eosin (D) and Immunostaining
for K14 and K1 (E) or for K5 and K8 (E), showing that
K14CreER:KRasG12D:p53fl/fl:Twist1fl/fl mice did not
develop any tumors, K14CreER:KRasG12D:
p53 fl/fl:Twist1fl/+ mice developed papilloma, while
K14CreER:KRasG12D:p53 fl/fl mice preferentially
develop SCCs.
Scale bars, 50 mm. Error bars represent SEM.
Cell Stem Cell
Twist1 in Skin Tumorigenesisskin cancer model (Figure 3A). Tamoxifen (TAM) administration
to K14CreER:KRasG12D:p53fl/fl mice led to the appearance of tu-
mors within 12 weeks (Figure 3B) that rapidly progress into inva-
sive SCC (Lapouge et al., 2011) (Figures 3C–3F). In sharp
contrast, TAM administration to K14CreER:KRasG12D:p53fl/fl:
Twist1fl/fl mice did not lead to the development of any tumor (Fig-
ures 3C–3F). This observation parallels the absence of tumor for-
mation in DMBA/TPA-treated mice upon Twist1 inactivation and
further confirms that Twist1 is required for skin tumor initiation.
Interestingly, deletion of only one allele of Twist1 (K14CreER:
KRasG12D:p53fl/fl:Twist1fl/+) did not change the number of tumors
formed (Figure 3C), but was sufficient to block the conversion of70 Cell Stem Cell 16, 67–79, January 8, 2015 ª2015 Elsevier Inc.papilloma to malignant SCCs, as illus-
trated by their benign histology (Figure 3D)
and the persistence of K10 expression; a
marker of differentiation in normal skin
and papilloma (Figure 3E), and the
absence of K8, a marker expressed in ma-
lignant skin SCC (Figure 3F). These results
indicate that different levels of Twist1 are
required for benign skin tumor initiation
and malignant progression and show
that low level of Twist1 is sufficient for
papilloma formation, while a higher level
of Twist1 that requires the expression of
both Twist1 alleles is necessary for malig-
nant progression.
Twist1 Controls Tumor Propagation
of Primary Skin Tumors
The gold standard assay to study cancer
stem cell properties is the transplantation
of limiting dilution of tumor cells to assess
their capacity to reform secondary tumors
into immunodeficient mice. Overexpres-
sion as well as short hairpin RNA-induced
knockdown of Twist1 in tumor cell lines af-
fects E-cadherin expression, EMT, and
the capacity of tumor cells to self-renew
in vitro and to be propagated into immunodeficient mice in vivo
(Mani et al., 2008; Morel et al., 2008). Hence, it was suggested
that EMT induces tumor stemness. To determine whether tumor
stemness and EMT are functionally linked, we first assessed in
our experimental system whether Twist1 regulates tumor-prop-
agating potential of primary skin tumors (Figure 4A). As previ-
ously reported (Lapouge et al., 2012), the transplantation of
106 total cells from papilloma, including tumor epithelial cells
(TECs) and stromal cells, induced the formation of secondary tu-
mors in about 80% of the recipient mice (Figure 4B). However,
none of the Twist1 deleted TECs were able to reform secondary
tumors in these experimental conditions (Figure 4B). Analysis of
A B
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Figure 4. Twist1 Controls Tumor Propaga-
tion of Primary Skin Tumors
(A) Experimental design to assess the role of
Twist1 in regulating tumor propagation into
immunodeficient mice.
(B and C) Table summarizing number of tumors
arising after the transplantation of different di-
lutions of Ctrl and Twist1 deficient papilloma TECs
or (C) SCC cells. Exact Fisher test was performed.
(D) Estimated frequency of TPCs in Ctrl,
K14CreER:Twist1fl/fl, and K14CreER:Twist1fl/+
SCC.
(E) qRT-PCR analysis of mRNA expression of EMT
related genes performed on FACS isolated TECs
from Ctrl and Twist1cKO mice 5 days after TAM
administration (n = 3).
(F) Immunostaining for K14, E-cadherin, and vi-
mentin in Ctrl and Twist1cKO SCC, showing that
Twist1 deletion leads to an upregulation of E-
cadherin in skin SCC.
Scale bars, 50 mm (see also Figure S3). Error bars
represent SEM.
Cell Stem Cell
Twist1 in Skin TumorigenesisCD34 and Sox2 expression, two well-characterized skin cancer
stem cell markers (Beck et al., 2011; Boumahdi et al., 2014;
Lapouge et al., 2012; Schober and Fuchs, 2011; Siegle et al.,
2014), showed no difference in the percentage of TEC express-
ing these two markers (Figures S3A–S3C), consistent with the
essential role of Twist1 in regulating TPC function in benign tu-
mors. To assess whether Twist1 also regulates the tumor-prop-
agating potential in more advanced tumors, we transplanted
FACS isolated TECs from SCC into immunodeficient mice
following Twist1 deletion and found that Twist1 deletion de-
creased the proportion of TPCs by 100-fold (Figures 4C and
4D), indicating that Twist1 indeed modulates tumor stemness
in both benign and malignant skin tumors. Interestingly, the
loss of a single Twist1 allele also greatly impaired tumor propa-
gation, suggesting that the level of Twist1 promotes tumor prop-
agation in a gene dosagemanner (Figures 4C and 4D). Moreover,
we observed that Twist1 deletion in SCC induced a small, but
significant, upregulation of E-cadherin at mRNA and protein level
(Figures 4E and 4F), suggesting that Twist1 regulates directly or
indirectly E-cadherin expression during malignant progression.
Twist1 Is Essential for Tumor Maintenance In Vivo
Independently of EMT
Our data indicate that Twist1 conditional deletion before or
concomitantly to oncogene expression prevents the initiation of
benign skin tumors and conditional deletion in pre-existing tu-Cell Stem Cell 16, 67–mors impairs their ability to be propagated
into immunodeficient mice. However, it
remains unclear whether Twist1 expres-
sion is required for the maintenance of
benign papillomas in vivo in their native tu-
mor environment. We therefore acutely
deleted Twist1 in papillomas by adminis-
tering TAM to K14CreER:Twist1fl/fl mice
displaying DMBA/TPA induced skin tu-
mors (Figures 5A and 5B). Remarkably,
while control papillomas continued togrow during the 2 weeks following TAM administration, Twist1
deletion induced rapid tumor regression and after 14 days of
treatment most of the skin papillomas had completely disap-
peared (Figure 5C). Twist1-deleted tumor cells were abnormally
large with big nuclei (Figure 5D), exhibited a strong decrease in
the tumor cellularity accompanied by a significant decrease in
TEC proliferation, and a marked increase in apoptosis (Figures
5E–5J and S4). These results show that in skin papilloma, Twist1
expression is required for tumor maintenance in vivo by promot-
ing proliferation and suppressing apoptosis.
Surprisingly, 7 days after TAM administration, immunostaining
performed on skin sections showed that Twist1-deficient tumor
cells express the same levels of E-cadherin as control tumors
(Figure 5K). Quantitative (q)RT-PCR performed on FACS-iso-
lated TECs confirmed that the levels of E-cadherin were not
affected by Twist1 deletion (Figure 5L) and showed no change
in the expression of mesenchymal markers (vimentin, fibro-
nectin, and N-cadherin) or other EMT-transcription factors
such as Snail, Slug, Zeb1, and Zeb2 (Figure 5L). These results
indicate that in skin papilloma, Twist1 regulates tumor mainte-
nance and tumor propagation independently of its ability to regu-
late expression of EMT-related genes.
Twist1 Inhibits p53 Stabilization in Primary Skin Tumors
Because Twist1-dependent tumor maintenance did not require
induction of EMT, we searched for alternative mechanisms by79, January 8, 2015 ª2015 Elsevier Inc. 71
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Figure 5. Twist1 Is Essential for Benign Tu-
mor Maintenance In Vivo Independently of
EMT
(A and B) Genetic strategy used to study the role of
Twist1 in the maintenance of tumor cells in primary
tumors vivo.
(C) Tumor size 0, 1, and 2 weeks after the
beginning of TAM treatment in Ctrl and
K14CreER:Twist1fl/fl mice (n = 26 from four
animals). This data show rapid tumor regression
upon Twist1 deletion.
(D) Hematoxylin/Eosin on tumors from Ctrl and
K14CreER:Twist1fl/fl mouse treated with TAM for
7 days.
(E) Immunostaining for K14 and Ki67 on Ctrl and
Twist1cKO tumors treated with TAM for 7 days.
(F) Quantification of the proportion of Ki67+ basal
TECs (n = 6/condition).
(G) Quantification of the proportion of BrdU+ basal
TECs (n = 4/condition).
(H) Immunostaining for active-caspase3 and K14
on tumors from a Ctrl and K14CreER:Twist1fl/fl
mouse treated with TAM for 5 days.
(I) Quantification of the proportion of active-
Caspase3+ TECs (n = 4/condition).
(J) Quantification of the proportion of TUNEL+
TECs (n = 5/condition), showing that cell death was
increased upon Twist1 deletion.
(K) Immunostaining for E-cadherin and K5 on Ctrl
and Twist1cKO tumors treated with TAM for
7 days, showing that Twist1 deletion does not lead
to E-cadherin upregulation.
(L) qRT-PCR analysis of EMT regulators, E-cad-
herin, and mesenchymal markers in Ctrl and
Twist1 deficient tumors treated with TAM for
7 days.
Scale bars, 50 mm (see also Figure S4). Error bars
represent SEM.
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Twist1 in Skin Tumorigenesiswhich Twist1 controls this process. Twist1 had been previously
reported to negatively regulate p53-signaling in response to
HRas- and Myc-induced oncogenic stress and to prevent onco-
gene-induced senescence in different cell lines in vitro (Ansieau
et al., 2008; Maestro et al., 1999; Valsesia-Wittmann et al., 2004).
To determine whether endogenous Twist1 regulates the mainte-72 Cell Stem Cell 16, 67–79, January 8, 2015 ª2015 Elsevier Inc.nance of skin tumors through similar
mechanisms, we searched for evidence
of p53 signaling upon Twist1 deletion in
pre-existing skin papillomas. Immuno-
staining analysis 5 days after TAM admin-
istration revealed that p53 was rapidly
stabilized in most TECs following Twist1
deletion, while p53 protein expression
was not detected in control papilloma
(Figures 6A and 6B). qRT-PCR analysis
of the expression of well-established
p53 target genes such as Noxa, Bad,
Bid, Bax, Mdm2, and p21 (Harris and Lev-
ine, 2005) showed that these genes were
upregulated in TECs following Twist1
deletion, thus providing further evidence
for an activation of p53 signaling pathway(Figure 6C). Immunostainings confirmed the upregulation of p21,
which mediates p53-dependent cell cycle arrest in TECs
following Twist1 deletion (Figures 6D and 6E). The prevention
of oncogene-induced p53-dependent senescence controlled
by Twist1 in vitro has been shown to involve the inhibition of
p19ARF expression (Ansieau et al., 2008; Valsesia-Wittmann
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Figure 6. Twist1 Inhibits p53 Stabilization in
Primary Skin Tumors
(A) IHC for p53 on tumors from a Ctrl and
K14CreER:Twist1fl/fl mouse treated with TAM for
5 days.
(B) Quantification of the proportion of basal p53
positive TECs, showing a massive increase in p53
expression following Twist1 deletion (n = 3).
(C) qRT-PCR analysis of p53 target genes per-
formed on FACS isolated TECs following TAM
administration to K14CreER:Twist1fl/fl mice (n = 3).
(D) IHC for p21 on tumors from a Ctrl and
K14CreER:Twist1fl/fl mice treated with TAM for
5 days.
(E) Quantification of the proportion of basal p21
positive TECs (n = 5).
(F) qRT-PCR analysis of the expression of senes-
cence associated genes on FACS isolated TECs
following TAM administration to K14CreER:
Twist1fl/fl mice.
(G) Immunostaining for p19 and K14 on tumors
from a Ctrl and K14CreER:Twist1fl/fl mouse treated
with TAM for 7 days.
(H) Quantification of the proportion of basal p19
positive TECs (n = 5).
(I) IHC for p16 on a tumor from a Ctrl and
K14CreER:Twist1fl/fl mouse treated with TAM for
5 days.
(J) Quantification of the proportion of basal p16
positive TECs (n = 3). IHC were counterstained
with Hematoxylin/Eosin.
Scale bars, 50 mm. Error bars represent SEM.
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Twist1 in Skin Tumorigenesiset al., 2004). To determine whether Twist1 sustains tumor prolif-
eration and maintenance by inhibiting the p19ARF-p53 axis, we
investigated the expression of p19 following inactivation of
Twist1 in skin tumors. qRT-PCR and immunostaining analyses
of p19, p16, as well as, glb1 (b-galactosidase) (Dimri et al.,
1995) and Fuca1 (a-Fucosidase) (Hildebrand et al., 2013), two
markers of oncogene induced senescence, revealed these
genes were expressed in skin papilloma, but were not upregu-
lated following Twist1 deletion (Figures 6F–6J). Altogether, these
results indicate that while p53 is rapidly activated following
Twist1 deletion in skin papilloma, which in turn induces the
expression of cell cycle arrest and proapoptotic p53 target
genes, p53 activation did not further induce the canonical senes-
cence pathway in these cells.
p53-Dependent and -Independent Functions of Twist1
in Skin Tumors
To determine whether the impact of Twist1 deletion on tumor
maintenance and propagation is strictly dependent on activation
of the p53 pathway, we generated double cKO mice
(K14CreER:Twist1fl/fl:p53fl/fl), allowing the specific ablation of
Twist1 and p53 simultaneously in pre-existing DMBA/TPA-
induced skin tumors (Figures 7A, 7B, and S5A–S5D). Control tu-
mors continued to grow following TAM administration, while
Twist1-inactivation alone led to tumor regression (Figure 7C).
In contrast, deletion of both Twist1 and p53 prevented tumorgrowth, but did not lead to tumor regression (Figure 7C), indi-
cating that p53 loss only partially rescues the impact of Twist1
deletion. Immunostaining analyses for apoptotic and prolifera-
tion markers showed that p53 deletion in Twist1-deficient cells
rescued apoptosis, but did not rescue cell proliferation (Figures
7D–7G). qRT-PCR performed on FACS-isolated TECs following
TAM administration confirmed the efficient deletion of p53 and
Twist1 in the different conditional KO mice and revealed the effi-
cient downregulation of the proapoptotic p53 target genes (Fig-
ure 7H). However, p21 was not downregulated either at the
mRNA or the protein level in Twist1/p53 double KO tumor cells
as compared to Twist1 single KO TECs (Figures S5C and
S5D), indicating that Twist1 regulates cell proliferation in skin tu-
mor independently of p53.
To determinewhether the p53-independent functions of Twist1
regulate tumor stemness, we assessed, using the standard assay
to assess tumor stemness (Magee et al., 2012), the ability of p53
deletion to rescue the decrease in tumor propagating potential
induced by Twist1 deletion. Transplantation of serial dilution of
TECs 7 days after TAM administration showed that p53 deletion
did not rescue the defect in TPCpotential inducedby Twist1 dele-
tion in primary skin SCCs (Figure 7I), supporting the notion that
Twist1 can regulate tumor stemness independently of p53.
To further characterize the mechanisms by which Twist1 reg-
ulates tumor maintenance and propagation independently of
p53 and of its ability to modulate EMT, we transcriptionallyCell Stem Cell 16, 67–79, January 8, 2015 ª2015 Elsevier Inc. 73
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Twist1 in Skin Tumorigenesisprofiled using microarray FACS isolated TECs from control,
Twist1cKO, and Twist1/p53cKO papilloma 5 days after TAM
administration. We found 43 common genes downregulated
and 78 common genes upregulated in both Twist1 single cKO
and Twist1/p53 double cKO (Figures 7J, S6, and S7). Since no
tumor regression was observed in Twist1/p53 double cKO, these
genes are unlikely to reflect an indirect effect of Twist1 deletion
on tumor regression. Importantly, we found that Twist1 deletion
leads to the downregulation of Nrp1 (Figure 7K), a vascular endo-
thelial growth factor (VEGF) coreceptor that we and others have
previously reported as a major regulator of CSC in skin tumors
(Beck et al., 2011; Siegle et al., 2014) and glioblastoma (Hamerlik
et al., 2012). In addition, we found that Twist1 deletion led to
decreased expression of phosphoglycerate dehydrogenase
(Phgdh), a metabolic enzyme overexpressed in tumor cells,
and whose knockdown induced decreased tumor cell prolifera-
tion (Locasale et al., 2011; Possemato et al., 2011). Twist1 dele-
tion also directly or indirectly caused changes in the expression
of other genes that promote proliferation (e.g., Etv3) and adhe-
sion/invasion (e.g., S100A4, Dpysl3, ccnb1ip1, and Dsg1a)
(Figure 7K).
DISCUSSION
While Twist1 is known for its ability to induce EMT, tumor pro-
gression, and dissemination (Chen and Behringer, 1995; Mani
et al., 2008; Morel et al., 2008; Yang et al., 2004), its role in tumor
initiation has not been investigated so far. Here, using condi-
tional deletion of Twist1 in the skin epidermis at different stages
of tumor initiation and progression, we demonstrate that Twist1
is expressed at early stages of tumorigenesis and is required for
the initiation of skin tumors. Strikingly, while deletion of both al-
leles of Twist1 is necessary to prevent tumor initiation, deletion of
a single allele is sufficient to prevent malignant progression.
Whether Twist1 is monoallelically expressed before SCC con-
version remains an open question. Although previous studies re-
ported that transgenic overexpression of Twist1 stimulates the
conversion of benign papilloma into malignant SCCs (Morel
et al., 2012; Tsai et al., 2012), our results establish a previously
unrecognized and essential role for Twist1 gene dosage in skin
tumor initiation and malignant progression. Deletion of Twist1
in SCCs, but not in benign papilloma, upregulates E-cadherinFigure 7. p53-Dependent and -Independent Functions of Twist1 in Ski
(A and B) Genetic strategy used to dissect the p53-dependent and -independen
(C) Tumor size 2 weeks after the beginning of TAM treatment in Ctrl, Twist1 cKO,
and p53 rescues tumor shrinkage that occurs following Twist1 deletion.
(D) Immunostaining for K14 and Ki67 on Ctrl, Twist1 cKO, and Twist1/p53 doubl
(E) Quantification of the proportion of Ki67+ basal TECs treated with TAM for 14
decrease in tumor proliferation mediated by Twist1 deletion.
(F) Immunostaining for active-caspase3 and K14 on Ctrl, Twist1 cKO, and Twist
(G) Quantification of the proportion of active-Caspase3+ TECs treated with TAM
apoptosis mediated by Twist1 deletion.
(H) qRT-PCR analysis of p53 related genes mRNA expression performed on FA
treated with TAM for 10 days.
(I) Table summarizing the number of tumors arising after the transplantation of d
treated with TAM for 10 days. These data show that p53 deletion does not rescu
(J) Venn diagram, showing the genes downregulated in both Twist1cKo and Twi
(K) qRT-PCR analysis of genes downregulated in both Twist1cKo and Twist1/p5
(L)Scheme representing thedynamic expressionand thedifferent rolesof Twist1du
Error bars represent SEM.expression, suggesting that higher levels of Twist are required
for EMT as compared to lower levels required for its role in tumor
initiation and maintenance.
Twist1 overexpression in breast cancer cell lines (Mani et al.,
2008; Morel et al., 2008) and glioblastoma (Mikheeva et al.,
2010) promotes EMT, in vitro proliferation, and tumor propaga-
tion into immunodeficient mice, raising the possibility that Twist1
controls tumor stemness through its EMT inductive properties.
By deleting Twist1 in pre-existing skin tumors, we confirm its
essential role for tumor maintenance in vivo and for tumor prop-
agation into immunodeficient recipient mice. However, we also
provide genetic evidence that in skin papilloma, Twist1 affects
tumor maintenance and propagation independently of its ability
to repress E-cadherin and to induce the EMT program, confirm-
ing that the mesenchymal phenotype and tumor initiating prop-
erties are not always linked (Celia`-Terrassa et al., 2012; Ocan˜a
et al., 2012; Sarrio et al., 2012). This finding demonstrates that
Twist1 exerts different functions (i.e., EMT and tumor propaga-
tion) during skin tumorigenesis, and that these different activities
are not necessarily functionally linked. A more general conclu-
sion from this finding is that EMT is not a sine qua non condition
for the establishment of tumor stemness in vivo.
Twist1 has been shown to prevent oncogene-induced apo-
ptosis and/or senescence (e.g., Ras and Myc) by repressing
the p16 and/or the p19ARF/p53 pathways (Ansieau et al.,
2008; Maestro et al., 1999; Valsesia-Wittmann et al., 2004).
Consistently, acute deletion of Twist1 in papilloma leads to a
rapid stabilization of p53 as evidenced by a significant increase
in the expression of its canonical target genes. However, the
activation of the p53 pathway in this experimental setting is not
the consequence of increased p19ARF expression and does
not lead to senescence. These data indicate that Twist1 is
capable of interfering with tumor suppression via distinct mech-
anisms depending on the cell types (breast, pancreas, or lung)
(Lee and Bar-Sagi, 2010; Mani et al., 2008; Morel et al., 2008;
Tran et al., 2012) and/or the nature and the extent of oncogene
activation. Some of the discrepancies can also be explained
by the fact that, in previous studies, oncogene activation was
mimicked through overexpression of the oncogenes in cultured
cells (Mani et al., 2008; Morel et al., 2008), whereas in our study,
the oncogene is expressed in vivo and under the control of its
native promoter/regulatory region. Different mechanisms haven Tumors
t functions of Twist1 in skin tumors.
and Twist1/p53 double KO mice, showing that concomitant deletion of Twist1
e cKO tumors treated with TAM for 10 days.
days (n = 6/condition). These data show that p53 deletion does not rescue the
1/p53 double KO tumors treated with TAM for 14 days.
for 14 days (n = 9/condition). These data show that p53 deletion rescues tumor
CS isolated TECs from Ctrl, Twist1 cKO, and Twist1/p53 double cKO tumors
ifferent dilutions of Ctrl and Twist1/p53 double cKO TECs from invasive SCCs
e the decrease in tumor propagating potential mediated by Twist1 deletion.
st1/p53 double cKO.
3 double cKO (n = 3/condition).
ringskin tumor initiation,maintenance, andprogression (seealsoFiguresS5–S7).
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following Twist1 loss of function in tumor cells (Ansieau et al.,
2008; Kwok et al., 2007; Lee and Bar-Sagi, 2010; Vichalkovski
et al., 2010), including a direct interaction between p53 and
Twist1 (Piccinin et al., 2012; Shiota et al., 2008). According to
these studies, Twist1 directly antagonizes p53 functions by pro-
moting Mdm2-mediated p53 degradation. Consistent with this
possibility, whereas p53 protein is undetectable in skin papil-
loma expressing Twist1, p53 protein, but not mRNA, rapidly ac-
cumulates upon Twist1 deletion. However, whether p53 stability
in skin papilloma is controlled through a direct interaction with
Twist1 will require further studies.
Concomitant deletion of p53 and Twist1 in tumors allowed us
to further dissect the p53-dependent and independent functions
of Twist1 in the control of apoptosis and tumor stemness. Impor-
tantly, we show that Twist1 prevents apoptosis by suppressing
p53-function and, at the same time, promotes tumor cell prolifer-
ation and propagation independently of p53. Using microarray
analysis of TECs following the deletion of Twist1 or Twist1 and
p53, we uncovered 121 genes positively and negatively regu-
lated by Twist1 independently of p53 function. We found that
Twist1 directly or indirectly promotes the expression of Nrp1, a
VEGF coreceptor that promotes tumor stemness and prolifera-
tion in skin tumors (Beck et al., 2011; Siegle et al., 2014). Twist1
also regulates directly or indirectly the expression of Phgdh, an
enzyme overexpressed in tumor cells essential for cancer cell
proliferation (Locasale et al., 2011; Possemato et al., 2011).
While it has been previously shown that overexpression of p53
dominant-negative mutant (p53-R175H) induces Twist1 expres-
sion in immortalized prostate cell lines (Kogan-Sakin et al., 2011),
our data show that Twist1 is expressed in KRasG12D p53-defi-
cient SCC, indicating that Twist1 expression in tumor cells is not
strictly dependent on p53. In addition, our data show that Twist1
is essential for the initiation and maintenance of p53-deficient
SCC. Together these results unambiguously establish both
p53-dependent and -independent roles for Twist1 in tumor initi-
ation, proliferation, apoptosis, and propagation.
In summary, our study uncovers a key role for Twist1 in the
early steps of tumor initiation and a dose-dependent role in ma-
lignant progression (Figure 7L). Our results also demonstrate that
the multiple functions of Twist1 including tumor initiation, pro-
gression, propagation, and EMT can be functionally uncoupled
and are regulated by different mechanisms. Due to the impor-
tance of Twist1 functions in regulating different aspects of
tumorigenesis, future studies will be required to better under-
stand the dynamic of Twist1 expression during tumor initiation,
progression, andmetastasis, asmetastatic colonization requires
the downregulation of Twist1 expression (Tsai et al., 2012) and
dissect in greater detail the molecular mechanisms underlying
Twist1 functions at each of these important steps during tumor-
igenesis. Such studies are likely to lead to the development of
therapeutic strategies aimed at interfering with the different
oncogenic functions of Twist1 in cancer.EXPERIMENTAL PROCEDURES
Mice
Nonobese diabetic (NOD)/severe combined immunodeficiency (SCID)/Il2Rg
null mice were obtained from Charles River. Twist1fl/fl (Chen et al., 2007),76 Cell Stem Cell 16, 67–79, January 8, 2015 ª2015 Elsevier Inc.K14CRE (Vasioukhin et al., 1999), K14CREER (Vasioukhin et al., 2001),
KRasLSL-G12D (Tuveson et al., 2004), and p53fl/fl (Jonkers et al., 2001) mice
have been obtained from the Mouse Mutant Resource Regional Center at
University of North Carolina, Chapel Hill, NC or obtained from Jackson Labo-
ratories. Mouse colonies were maintained in a certified animal facility in accor-
dance with the European guidelines.
Mice were treated with DMBA and TPA as previously described (Beck et al.,
2011; Lapouge et al., 2012). Mice were treated three times at postnatal day 23,
25, and 27 with DMBA (50 mg) and then treated twice weekly with TPA (2.5 mg)
until their sacrifice. K14CreER:KRasLSL-G12D:p53fl/fl mice were treated with
TAM resuspended in sunflower oil at postnatal day 23 and 25 (2.5 milligrams
[mg]/injection) as previously described (Lapouge et al., 2011).
Measurement of Tumor Growth
Skin tumors were measured using a precision calliper. Tumor volumes were
calculated using the formula V = p 3 [d2 3 D] / 6, where d is the minor tumor
axis and D is the major tumor axis.
Immunostaining
Optimal cutting temperature (OCT) (Tissue Tek) embedded samples were
sectioned at 6 mm sections using CM3050S cryostat (Leica Microsystems)
and fixed in 4% paraformaldehyde for 10 min at room temperature. Nonspe-
cific antibody binding was prevented by incubating the slides with 5% horse
serum (HS), 1% BSA, and 0.2% Triton X-100 for 1 hr at room temperature. Pri-
mary antibodies were incubated overnight at 4C in blocking buffer. Sections
were rinsed three times in PBS and incubated with secondary antibodies
diluted at 1:400 for 1 hr at room temperature. Nuclei were stained in Hoechst
solution (4 millimolar) and slides were mounted using Glycergel (Dako) supple-
mented with 2.5% 1,4-diazabicyclo(2.2.2)octane (Sigma-Aldrich).
For immunohistochemistry (IHC), 5-mm paraffin sections were deparaffi-
nized and rehydrated. The antigen unmasking procedure was performed for
25 min at 98C in citrate buffer (pH 6) + Tween 0.05% using the pretreatment
module (labvision). Endogenous peroxydase was blocked using 3% H2O2
(Merck) in methanol (VWR) for 10min at room temperature. Endogenous avidin
and biotin were blocked using the Endogenous Blocking Kit (Invitrogen) for
20 min at room temperature. Mouse on mouse blocking kit was then used to
block unspecific epitopes according to the manufacturer guideline (MOM,
Vector Labs). For Twist1 staining, slides were incubated in a blocking solution
with 5% HS, 1% BSA, and 0.2% Triton X-100 for 30 min at room temperature
before incubation in theMOM blocking. Mouse anti-Twist1 antibody was incu-
bated overnight at 4C. Anti-mouse biotinylated (1/1,000 for 30 min at room
temperature), Standard ABC Kit, and ImmPACT DAB (Vector Laboratories)
were used for the detection of HRP activity. Slides were then dehydrated
and mounted using Safemount (Labonord).
Antibodies
The primary antibodies used are listed in the Supplemental Experimental
Procedures.
Microscopy
Microscope acquisition was performed on a Zeiss Axio Imager.M1 fluores-
cence microscope with a Zeiss Axiocam MR3 camera for immunofluores-
cence microscopy and a Zeiss AxioCam MRc 5 camera for bright-field micro-
scopy using AxioVision release 4.6 software.
FACS Isolation of Tumor Cells
Tumors were digested in collagenase I (Sigma) (2.5 mg/ml) for 2 hr at 37C on a
rocking plate. TECs were sorted based on expression of Epcam and absence
of lineage negative markers (CD45, CD31, and CD140a), living Epcam+/
CD45-/CD31-/CD140a-. Fluorescence-activated cell sorting analysis was per-
formed using FACSAria and FACSDiva software (BD Biosciences). Sorted
cells were collected at 4C either in culture medium for in vivo transplantation
experiments and into lysis buffer for RNA extraction.
Tumor Transplantation into Immunodeficient Mice
For transplantation of papilloma cells, total living cells were sorted based on
Hoechst dye exclusion, then resuspended in 50 ml of Matrigel (E1270,
970 mg/ml; Sigma) and injected subcutaneously to NOD/SCID/Il2Rg null
Cell Stem Cell
Twist1 in Skin Tumorigenesismice (Charles River). For transplantation of SCC cells, different dilutions of
Lin-/Epcam+ TECs resuspended in 50 ml of Matrigel were injected subcutane-
ously to NOD/SCID/Il2Rg null mice. Technical triplicates injections per mouse
were performed. In both cases, graftedmicewere treatedwith TAMat day 3, 5,
and 7 after transplantation (2.5 mg/injection). Secondary tumors were de-
tected by palpation every week and their size monitored until tumor reached
1 cm3 or when mice presented signs of distress, and the mice were sacrificed.
Estimation of the relative frequency of cancer propagating cells was per-
formed using the extreme limiting dilution analysis (ELDA) as described (Hu
and Smyth, 2009) and calculated using the ELDA online software (http://
bioinf.wehi.edu.au/software/elda/). The statistical p value was obtained using
a Chi-square test.
Conditional Deletion of Twist1 in Pre-existing Tumor Cells
K14CreER:Twist1fl/fl and K14CreER:Twist1fl/fl:p53fl/fl and their littermate con-
trols (K14CreER negative) were treated with DMBA/TPA as described above.
After tumor appearance, mice were injected intraperitoneally with two cycles
of 2 mg TAM per day during five consecutive days. Tumors were measured,
as described above, on the day of injection, 7, and 14 days later to quantify tu-
mor growth.
RNA Extraction, DNA Extraction, and qRT-PCR
RNA extraction was performed using the RNeasy Micro Kit (QIAGEN) accord-
ing to themanufacturer’s recommendations. Purified RNAwas used to synthe-
size the first strand cDNA using Superscript II (Invitrogen) and random hexam-
ers (Roche). qRT-PCR analyses were performed with 2 nanograms of cDNA as
template, using a SYBR Green Mix (Applied Bioscience) and an Agilent Tech-
nologies Stratagene Mx3500P real-time PCR System.
Relative quantitative RNA was normalized using the housekeeping gene
b-actin. Primers were designed using NCBI Primer-BLAST (http://www.ncbi.
nlm.nih.gov/tools/primer-blast/). Analysis of the results was performed using
MxPro Software (Stratagene) and relative quantification was performed using
the DDCt method using b-actin as a reference. The entire procedure was
repeated in at least three biologically independent samples.
All the primers used for genotyping and qPCR are listed in the Supplemental
Experimental Procedures.
Microarray
RNA was extracted from FACS isolated TECs as described above. There were
two control samples and two Twist1cKO samples that were sent to AROS
Applied Biotechnology A/S (Aarhus) and analyzed on Affymetrix 430 2.0 chips.
There were two control samples and two Twist1cKO:p53cKO samples that
were sent to the IRB Functional Genomics Core and analyzed on Affymetrix
430 PM chips. Signals were normalized using frozen robust multiarray analysis
to avoid batch effect (McCall et al., 2010). The list of genes upregulated and
downregulated more than two times in Twist1cKO and in Twist1/p53cKO
compared to their respective control was compared to find the common genes
shown in Figures S6 and S7.
Twist1 Expression in Human Skin SCCs
Tissue samples were obtained from archival formalin-fixed and paraffin-
embedded samples from five normal skins and 32 skin SCCs collected in
the Department of Pathology of the Erasme Hospital, Brussels, Belgium. The
5-mm-thick sections were subjected to standard IHC as previously described
(Boumahdi etal., 2014). TheexpressionofTWISTwasdetectedby immunostain-
ing using a mouse monoclonal anti-TWIST antibody (clone Twist2c1a, 1:25).
A case was considered as positive if some positive nuclei were noted in TECs.
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